

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 - 58 (Cancelled)

59. (New). A kit comprising:

(i) a container comprising a therapeutically effective amount of a gastrin/CCK receptor ligand; and

(ii) a container comprising a therapeutically effective amount of an EGF receptor ligand,

wherein said gastrin/CCK receptor ligand and said EGF receptor ligand of (i) and (ii) are in suitable form for administration by injection to a human patient, and said therapeutically effective amount of gastrin/CCK receptor ligand or EGF receptor ligand is about 1.4 to about 35 mg.

60. (New). The kit according to claim 59, wherein the EGF receptor ligand is selected from the group consisting of EGF1-53, EGF1-48, EGF1-52, EGF1-49, EGF1-47 congener of EGF1-48, and EGF1-49 congener of EGF1-48.

61. (New). The kit according to claim 59, wherein the gastrin/CCK receptor ligand is a gastrin 34, gastrin 17, or gastrin 8.